DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
7.71
+0.12 (1.58%)
Mar 6, 2026, 4:00 PM EST - Market closed
DiaMedica Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
28
Market Cap
413.09M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Niagen Bioscience | 129.42M |
| Sutro Biopharma | 105.65M |
| Autolus Therapeutics | 51.13M |
| Crescent Biopharma | 10.84M |
| PureTech Health | 6.39M |
| Immutep | 5.28M |
| Armata Pharmaceuticals | 5.05M |
| Upstream Bio | 2.80M |
DMAC News
- 2 days ago - DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia - Business Wire
- 11 days ago - DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences - Business Wire
- 7 weeks ago - DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA - Business Wire
- 4 months ago - DiaMedica Therapeutics Inc. (DMAC) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights - Business Wire
- 4 months ago - DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London - Business Wire
- 4 months ago - DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025 - Business Wire